Literature DB >> 32750526

Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors.

Darren W Engers1, Sean R Bollinger1, Andrew S Felts1, Anish K Vadukoot2, Charles H Williams3, Anna L Blobaum1, Craig W Lindsley4, Charles C Hong3, Corey R Hopkins5.   

Abstract

The activin-like kinases are a family of kinases that play important roles in a variety of disease states. Of this class of kinases, ALK2, has been shown by a gain-of-function to be the primary driver of the childhood skeletal disease fibrodysplasia ossificans progressiva (FOP) and more recently the pediatric cancer diffuse intrinsic pontine glioma (DIPG). Herein, we report our efforts to identify a novel imidazo[1,2-a]pyridine scaffold as potent inhibitors of ALK2 with good in vivo pharmacokinetic properties suitable for future animal studies.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ALK2; ALK3; Activin-like kinase inhibitors; BMP inhibitors

Mesh:

Substances:

Year:  2020        PMID: 32750526      PMCID: PMC7494637          DOI: 10.1016/j.bmcl.2020.127418

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  27 in total

1.  Bone morphogenetic protein signaling promotes tumorigenesis in a murine model of high-grade glioma.

Authors:  Laura D Hover; Philip Owens; Alexander L Munden; Jialiang Wang; Lola B Chambless; Corey R Hopkins; Charles C Hong; Harold L Moses; Ty W Abel
Journal:  Neuro Oncol       Date:  2015-12-18       Impact factor: 12.300

2.  In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors.

Authors:  Jijun Hao; Joshua N Ho; Jana A Lewis; Kaleh A Karim; R Nathan Daniels; Patrick R Gentry; Corey R Hopkins; Craig W Lindsley; Charles C Hong
Journal:  ACS Chem Biol       Date:  2010-02-19       Impact factor: 5.100

3.  Development of an ALK2-biased BMP type I receptor kinase inhibitor.

Authors:  Agustin H Mohedas; Xuechao Xing; Kelli A Armstrong; Alex N Bullock; Gregory D Cuny; Paul B Yu
Journal:  ACS Chem Biol       Date:  2013-04-30       Impact factor: 5.100

4.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Meiqi Xu; George J Feldman; David A Fenstermacher; Tae-Joon Cho; In Ho Choi; J Michael Connor; Patricia Delai; David L Glaser; Martine LeMerrer; Rolf Morhart; John G Rogers; Roger Smith; James T Triffitt; J Andoni Urtizberea; Michael Zasloff; Matthew A Brown; Frederick S Kaplan
Journal:  Nat Genet       Date:  2006-04-23       Impact factor: 38.330

Review 5.  ALK1 as an emerging target for antiangiogenic therapy of cancer.

Authors:  Sara I Cunha; Kristian Pietras
Journal:  Blood       Date:  2011-04-05       Impact factor: 22.113

6.  One-step synthesis of saturated spirocyclic N-heterocycles with stannyl amine protocol (SnAP) reagents and ketones.

Authors:  Woon-Yew Siau; Jeffrey W Bode
Journal:  J Am Chem Soc       Date:  2014-12-09       Impact factor: 15.419

7.  BMP type I receptor inhibition reduces heterotopic [corrected] ossification.

Authors:  Paul B Yu; Donna Y Deng; Carol S Lai; Charles C Hong; Gregory D Cuny; Mary L Bouxsein; Deborah W Hong; Patrick M McManus; Takenobu Katagiri; Chetana Sachidanandan; Nobuhiro Kamiya; Tomokazu Fukuda; Yuji Mishina; Randall T Peterson; Kenneth D Bloch
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440

8.  Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.

Authors:  Jian-Kang Jiang; Xiuli Huang; Khalida Shamim; Paresma R Patel; Arthur Lee; Amy Q Wang; Kimloan Nguyen; Gregory Tawa; Gregory D Cuny; Paul B Yu; Wei Zheng; Xin Xu; Philip Sanderson; Wenwei Huang
Journal:  Bioorg Med Chem Lett       Date:  2018-09-06       Impact factor: 2.823

9.  Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.

Authors:  Deeba Ensan; David Smil; Carlos A Zepeda-Velázquez; Dimitrios Panagopoulos; Jong Fu Wong; Eleanor P Williams; Roslin Adamson; Alex N Bullock; Taira Kiyota; Ahmed Aman; Owen G Roberts; Aled M Edwards; Jeff A O'Meara; Methvin B Isaac; Rima Al-Awar
Journal:  J Med Chem       Date:  2020-05-05       Impact factor: 7.446

10.  Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.

Authors:  Kathryn R Taylor; Alan Mackay; Nathalène Truffaux; Yaron Butterfield; Olena Morozova; Cathy Philippe; David Castel; Catherine S Grasso; Maria Vinci; Diana Carvalho; Angel M Carcaboso; Carmen de Torres; Ofelia Cruz; Jaume Mora; Natacha Entz-Werle; Wendy J Ingram; Michelle Monje; Darren Hargrave; Alex N Bullock; Stéphanie Puget; Stephen Yip; Chris Jones; Jacques Grill
Journal:  Nat Genet       Date:  2014-04-06       Impact factor: 38.330

View more
  1 in total

Review 1.  Therapeutic Targets in Diffuse Midline Gliomas-An Emerging Landscape.

Authors:  Elisha Hayden; Holly Holliday; Rebecca Lehmann; Aaminah Khan; Maria Tsoli; Benjamin S Rayner; David S Ziegler
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.